Pregabalin Withdrawal: Symptoms, Timeline and How to Stop Safely

Pregabalin withdrawal typically begins 24 to 48 hours after the last dose, peaks in the first week, and lasts 1 to 2 weeks for most people. Long-term or high-dose users can feel lingering symptoms for months. Stopping abruptly can trigger seizures, so the NHS is clear: never stop without speaking to your doctor. This guide explains what to expect and how a supervised taper protects you.

What is pregabalin and why does it cause withdrawal

Pregabalin is a prescription drug sold under the brand name Lyrica and as several generics. UK use of pregabalin and gabapentin covers fibromyalgia and neuropathic pain, generalised anxiety disorder (GAD), and partial-onset epileptic seizures. Pregabalin use has risen since 2010, and so have prescriptions linked to dependence.

It binds to the alpha-2-delta subunit of voltage-gated calcium channels in the brain, dampening overactive nerve signalling and reducing release of excitatory neurotransmitters. With sustained use the nervous system adapts to that dampening, and reducing or stopping the medicine causes a rebound that can lead to withdrawal symptoms.

Both people taking pregabalin exactly as prescribed and those with substance abuse patterns can develop physical dependence. That is why withdrawal effects reach a wider group than many assume, including people who have never thought of themselves as having a problem with prescription drug use.

Pregabalin withdrawal symptoms

Withdrawal symptoms of pregabalin are physical and psychological, plus a smaller set of severe withdrawal symptoms that need urgent care. The list below reflects symptoms reported on the NHS pregabalin page and in a peer-reviewed case report and review of the literature (Ishikawa et al, 2021).

Physical symptoms

• Headaches, dizziness, sweating, palpitations
• Nausea, vomiting, diarrhoea
• Restlessness, tremor, muscle pain, chest tightness
• Insomnia and disturbed sleep

Psychological symptoms

• Anxiety, agitation and mood swings
• Depression and low mood
• Confusion, concentration problems and cravings

Serious complications – seek help immediately

• Seizures, especially in people with epilepsy or a high-dose history
• Suicidal thoughts or behaviour
• Severe respiratory difficulty, particularly when pregabalin has been mixed with opioids, benzodiazepines or alcohol
• Angioedema (rare but life-threatening swelling of face, lips or throat)

If any serious complication occurs, call 999 or go straight to A&E.

The pregabalin withdrawal timeline

The pattern below is typical, based on NHS guidance and published case data. Individual experience varies, especially for long-term or high-dose users.

Ishikawa et al found symptoms emerging 1 to 7 days after the last dose, even at standard prescribed doses (150 to 600mg per day).

Who experiences worse withdrawal

Several factors raise the risk of severe or prolonged withdrawal effects. The more of these that apply, the stronger the case for medical supervision over a DIY taper.

• A daily dose above 300mg, particularly above 450mg
• Long length of use, often years rather than months
• A history of seizures or epilepsy
• Mixing pregabalin with alcohol, opioids, benzodiazepines or other sedatives
• Older age (65 plus) or impaired kidney function
• Co-occurring anxiety, depression, PTSD or chronic pain

Pregabalin dependence is not the same as addiction

Pregabalin dependence develops in many people who use it exactly as directed for nerve pain, anxiety or epilepsy. It is the body adapting to a regular dose of pregabalin, not a moral failing.

Addiction is different. It involves compulsive use, escalating doses without medical reason, and continued use despite harms. People can become dependent without ever becoming addicted, even at standard doses of pregabalin.

If you have taken pregabalin as prescribed and now want to stop taking it, you deserve calm, judgement-free support. The same is true if your relationship with pregabalin has tipped into pregabalin misuse. Both groups need a properly managed taper.

Why pregabalin is a Class C controlled drug in the UK

Gabapentin and pregabalin were reclassified as Class C controlled substances under Schedule 3 on 1 April 2019. The MHRA acted after gabapentinoids were implicated in around one fifth of drug-related deaths in Scotland in 2016 and after 113 reports of pregabalin abuse and 98 of dependence reached the regulator. UK prescriptions are now limited to 30 days and dispensed within 28. Gabapentin withdrawal follows a similar pattern but most published case data is on pregabalin.

Despite the reclassification, ONS data shows death registrations mentioning pregabalin in England and Wales rose from 187 in 2018 to 441 in 2022. The increase in the number of cases largely reflects co-use of opioids, which makes dangerous withdrawal common when pregabalin is stopped without medical oversight.

How to stop pregabalin safely

The most important rule: do not stop pregabalin abruptly. The NHS warns that abrupt discontinuation of pregabalin can cause seizures that will not stop, particularly in people taking it for epilepsy.

NICE guideline NG215 confirms that tapering off pregabalin can take weeks to months. Prescribers should pause or step the dose back up if symptoms of pregabalin withdrawal become intolerable.

Most NHS regional gabapentinoid deprescribing guidelines, including Sheffield and Ayrshire & Arran, advise that you reduce the dose by no more than 50 to 100mg per week. The dose reduction may need to be slower (around 25mg every 1 to 2 weeks) for long-term users, high-dose users, and anyone struggling with pregabalin withdrawal during the taper. Your GP, pain specialist or psychiatrist should plan your taper. This guide is not a substitute for personalised clinical advice.

Sample pregabalin tapering schedule (illustrative)

The schedule below is illustrative only. Real tapering schedules are agreed with a clinician and adjusted as you respond.

Contact your prescriber straight away if you experience seizures, suicidal thoughts, severe insomnia, signs of angioedema or any symptom you cannot manage at home.

Mixing pregabalin with alcohol, opioids or benzodiazepines

Pregabalin is a central nervous system depressant. Combining it with other depressants raises the risk of severe sedation, respiratory depression and overdose, and that risk persists into the early days of any withdrawal attempt.

The MHRA has warned about severe respiratory depression with pregabalin, with people over 65, those with kidney impairment, and those on opioids at highest risk. A 2022 BJCP analysis found that 92% of gabapentinoid-related deaths in England 2004-2020 involved co-detected opioids. Anyone tapering pregabalin while still using opioids, benzodiazepines, alcohol or sleeping tablets needs medical oversight.

Home detox vs supervised detox

Both treatment options have a place. The right choice depends on your dose, history, and home environment.

Steps Together offers both home detox programmes and inpatient care, depending on need.

What supervised pregabalin detox involves

A medically supervised detox is structured inpatient treatment that contains the risks the NHS warns about while supporting recovery. At a CQC-regulated facility it typically includes:

• Pre-admission medical assessment of dose, duration, other medicines and physical health
• 24/7 medical cover with vital sign and seizure monitoring
• A personalised tapering schedule adjusted day to day
• Anti-seizure cover plus medication for anxiety, nausea and sleep
• One-to-one therapy and group sessions
• A trigger-free environment for the hardest first 7 to 14 days

Steps Together provides medically supervised drug detox at residential locations including The Chestnuts, Bank House and Rainford Hall. Read more about our pregabalin rehab and detox programme.

Treatment after pregabalin detox

Detox stabilises the body. It rarely resolves the reason pregabalin was prescribed in the first place. Comprehensive addiction treatment after detox addresses the pain, anxiety, trauma or low mood that pregabalin was managing.

Evidence-based therapies at our drug rehab programmes include CBT, DBT, EMDR and group therapy. For co-occurring mental health conditions, dual diagnosis treatment addresses both at once in residential treatment. Recovery does not end at discharge: structured aftercare includes follow-up therapy, peer support, and a relapse prevention plan.

Worried about coming off pregabalin Speak to our team in confidence Whether you are tapering on prescription or trying to come off pregabalin after misuse, our admissions team can talk you through your options. CQC-regulated. UK-based. Confidential. Speak to our admissions team | Call +44 330 053 3962 CQC-regulated. Confidential. No obligation.

Sources

1. NHS – “Pregabalin: how and when to take it” – https://www.nhs.uk/medicines/pregabalin/how-and-when-to-take-pregabalin/
2. GOV.UK MHRA Drug Safety Update – “Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April 2019” – https://www.gov.uk/drug-safety-update/pregabalin-lyrica-gabapentin-neurontin-and-risk-of-abuse-and-dependence-new-scheduling-requirements-from-1-april
3. NICE – “NG215 Recommendations: Medicines associated with dependence or withdrawal symptoms” – https://www.nice.org.uk/guidance/ng215/chapter/Recommendations
4. Office for National Statistics – “Drug related deaths where Gabapentin or Pregabalin were mentioned, England and Wales: 2018 to 2022” – https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/adhocs/2154drugrelateddeathswheregabapentinorpregabalinwerementionedenglandandwales2018to2022
5. Ishikawa H, Takeshima M, Ishikawa H, et al. – “Pregabalin withdrawal in patients without psychiatric disorders taking a regular dose of pregabalin: A case series and literature review” Neuropsychopharmacology Reports 2021 – https://pmc.ncbi.nlm.nih.gov/articles/PMC8411313/
6. GOV.UK MHRA Drug Safety Update – “Pregabalin (Lyrica): reports of severe respiratory depression” – https://www.gov.uk/drug-safety-update/pregabalin-lyrica-reports-of-severe-respiratory-depression
7. Kalk NJ, et al. – “Fatalities associated with gabapentinoids in England (2004-2020)” British Journal of Clinical Pharmacology, 2022 – https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15352